Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

311 questions · 322 findings · 24 reviews · Headline outcomes only

No studies found 78 · 24.2%GRADE not reported 12 · 3.7%Very low 76 · 23.6%Low 76 · 23.6%Moderate 65 · 20.2%High 15 · 4.7%

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention probably leads to higher teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (moderate certainty).

1 finding from 1 review

Intervention not reported

Interferon beta‐1b (Betaferon) No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

It is very uncertain whether the intervention changes interferon beta‐1b (Betaferon) No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560… (low certainty).

1 finding from 1 review

Pentoxifylline with antibiotics (any dose or duration) vs pentoxifylline with antibiotics and immunoglobulin M‐enriched intravenous immunoglobulin

Necrotising enterocolitis · neonates with sepsis

It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).

1 finding from 1 review

Pentoxifylline with antibiotics (any dose or duration) vs immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics

All‐cause mortality during hospital stay · neonates with sepsis

It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).

1 finding from 1 review

Pentoxifylline with antibiotics (any dose or duration) vs immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics

Necrotising enterocolitis · neonates with sepsis

It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).

1 finding from 1 review

Pentoxifylline with antibiotics (any dose or duration) vs pentoxifylline with antibiotics and immunoglobulin M‐enriched intravenous immunoglobulin

All‐cause mortality during hospital stay · neonates with sepsis

It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs human immunoglobulin

All‐cause mortality at up to day 28 · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 compared with human immunoglobulin (low certainty).

1 finding from 1 review